CClinicalTrials.gg
CompletedNCT05453266Updated Jul 12, 2022

Arthroscopic Rotator Cuff Repair Performed With Intraarticular Tranexamic Acid Could it Provide Improved Visual Clarity and Less Post-operative Pain? A Prospective, Double Blind, Randomized Study of 64 Patients.

An interventional study of Application of Tranexamic acid in arthroscopic irrigation solution and No application of Tranexamic acid in arthroscopic irrigation solution in Rotator Cuff Tears, Rotator Cuff Rupture and Tranexamic Acid, sponsored by Florence Nightingale Hospital, Istanbul. Completed at 1 site in Turkey. Per ClinicalTrials.gov, last updated 2022-07-12.

Sponsored by Florence Nightingale Hospital, Istanbul · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jan 2022, registered Jun 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
63
Allocation
Randomized
Sex
All
01

Study summary

Shoulder arthroscopy is widely used for treatment of different shoulder pathologies. Visual clarity is essential for successful and safe surgery. The aim of present study is to determine whether intraarticular use of tranexamic acid (TXA) in surgery fluid can improve visual clarity and early postoperative pain.

Read the detailed description

Patients and Methods After obtaining institutional review board approval (Istanbul Yeni Yuzyil University, Nr: 13.02.2020/009) together with the registry to ClinicalTrials.gov, patients were prospective enrolled in this observational study, which was designed as double-blind, placebo-controlled and randomized.

Inclusion criteria were defined as: being older than 18 years of age, having an MRI confirmed rotator cuff rupture with a history of failure of conservative treatment of at least 6 months, being willing to participate to the clinical trial.

Patient Selection Exclusion criteria were defined as: patients with a history of coagulopathy, deep venous thrombosis, tendency to thrombotic events, patients under anti-coagulant therapy, patients with inferior vena cava filter, patients with abnormal prothrombin time-activated partial thromboplastin time-bleeding time, patients with a history of cardiac/renal/hepatic disease, patients with a diagnosis of TXA allergy, patients with an acute RCT, having been treated conservatively for less than 6 months, being under the age of 18. Table 1.

As a result of the inclusion/exclusion criteria, 42 patients (14 had acute RCT, 12 were receiving anti-coagulant therapy, 9 had history of cardiac/hepatic/renal disease, 5 had abnormal PT-aPTT value at the time of the diagnosis, 2 had received conservative treatments for less than 6 months for RCR) were excluded from 105 patients, who were eligible and were willing to participate. The remaining 63 patients were enrolled in the study. Table 2 (Flowchart). All patients provided informed consents, so that their pre-operative, intra-operative and post-operative data including imaging studies and arthroscopic images could be used for publication by concealing their identity.

Randomization By using computer based randomization software acquired from random.org, patients were randomized into two groups comprising a TXA group (n=32, 24M, 8F) (TXA Group) and a control group (n=31, 22M,9F) (Control Group), while group information was neither shared with patients nor with the operating surgeon as a result of double-blind nature of the study.

Double-blinded preparation of the Irrigation Solutions To conduct a double-blinded, randomized control study, arthroscopic irrigation solutions (normal saline) of 3 liters were prepared by an operating nurse, while 250 mg TXA was injected into irrigation solutions of Group 1, and irrigation solutions of Group 2 were left TXA-free without any injection.

Surgical Procedures All procedures were performed under general anesthesia in beach-chair position by the same surgeon (C.B.) by following the exact same surgical steps in the exact same sequence irrespective of the patient's assignment to TXA group or control group. The surgical procedure comprised thorough evaluation of the glenohumeral joint, together with the rotator interval. In case of a degenerative biceps tendon, a biceps tenotomy was undertaken (TXA Group: 28 patients, Control Group: 26 patients). The repair of supraspinatus tendon was undertaken by utilizing single-row technique. A pressure-controlled pump was used to keep the pressure of the irrigation solution constantly at 50 mmHg. When visibility was decreased as a result of hemorrhage, the pressure was increased by 20 mmHg by using the flush option of the device. During the operation, mean arterial pressure was recorded by the anesthesiologist.

Assessment of Intra-Operative Arthroscopic Visual Clarity and Secondary Outcome Parameters Single surgeon (CB) rated arthroscopic visual score (AVS) similar to the grading system used by van Montfoort21 was used to evaluate intra-operative clarity. AVS was composed of five grades: Grade I: I had no disruption of visual clarity due to bleeding.

Grade II: I had mild disruption of visual clarity due to bleeding. Grade III: I had moderate disruption of visual clarity due to bleeding. Grade IV: I had severe disruption of visual clarity due to bleeding. Grade V: As a result of extreme disruption of visual clarity due to bleeding, I had to convert to open surgery.

AVS score for every patient was calculated as the following: The video of the operation was watched by the operating surgeon (CB) after the surgery and at every 15 minutes, a score of AVS was recorded. At the end, the average score for every single patient was calculated.

Pain was evaluated by using visual analogue scale (VAS) post-operative 8th, 24th and 48th hour.

Patients' mean arterial pressures (MAP) and total duration of operations were recorded.

All of the average aforementioned data of the two groups were compared. Post-operative Patient Management Patients were applied abduction brace after the operation and they were advised to limit the active shoulder range of motion together with abduction during their stay in the hospital.

Pain management was performed by 500 mg paracetamol injection at every 8 hours and intramuscular injection of ketorolac at 24 hours. Patients were discharged at the second post-operative day, when they were confirmed to be stable with tolerable pain.

Statistical method To calculate the sample size, G-Power software (gpower.hhu.de, v 3.1.9.4) was used, while a statistical power (1-ß), alpha error and impact value were calculated as 0.8, 0.05 and 0.8 respectively. As a result of this priori power analysis model, at least 30 speciments were calculated to be required in each group, which was consistent with out design.

For the statistical analysis SPSS software (Version 25.0; SPSS Inc, Chicago, IL, USA) was used. Data are expressed as mean +/- SD (standard deviation). The cohort and the variables were tested for normal distribution and data normality was confirmed by Shapiro-Wilk test. Age, sex, surgery time, mean arterial blood pressure, surgical visaualization score, AVS and postoperative pain scores were compared between groups. Demographic characteristics of the patients were analyzed using descriptive statistics analysis methods, with mean and standard deviation. Normality analysis was made with different methods including histogram, kurtosis and skewness test. Independent sample t-test was used to compare the difference between groups. Analysis of postoperative pain scores at different time points scores within the groups at different time points was made with repeated measures ANOVA test. Results were reported at a 95% confidence interval, and P values \<0.05 were considered statistically significant.

02

Conditions studied

  • Rotator Cuff Tears
  • Rotator Cuff Rupture
  • Tranexamic Acid
  • Shoulder Arthroscopy
  • Visual Clarity

Keywords

  • Rotator cuff tear
  • Rotator cuff rupture
  • Tranexamic acid
  • Shoulder arthroscopy
  • Visual clarity
03

In context

Pain, Postoperative

5,093 studies on the registry are indexed under Pain, Postoperative; 1,140 are open to participants now.

This study's enrollment of 63 is below the median of 75 across 4,344 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

Florence Nightingale Hospital, Istanbul is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • being older than 18 years of age,
  • having an MRI confirmed rotator cuff rupture with a history of failure of conservative treatment of at least 6 months,
  • being willing to participate to the clinical trial.

Exclusion criteria

Exclusion Criteria:

  • patients with a history of coagulopathy, deep venous thrombosis, tendency to thrombotic events,
  • patients under anti-coagulant therapy,
  • patients with inferior vena cava filter,
  • patients with abnormal prothrombin time-activated partial thromboplastin time-bleeding time,
  • patients with a history of cardiac/renal/hepatic disease,
  • patients with a diagnosis of TXA allergy,
  • patients with an acute RCT, having been treated conservatively for less than 6 months,
  • being under the age of 18
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
63 participants (actual)

Study arms

  • Active comparator
    TXA Group

    Patients with rotator cuff tear, operated arthroscopically under intraarticularly applied tranexamic acid in arthroscopic irrigation solution.

    Procedure: Application of Tranexamic acid in arthroscopic irrigation solution

  • Placebo comparator
    Control group

    Patients with rotator cuff tear, operated arthroscopically without intraarticularly applied tranexamic acid in arthroscopic irrigation solution.

    Procedure: No application of Tranexamic acid in arthroscopic irrigation solution

Interventions

  • ProcedureApplication of Tranexamic acid in arthroscopic irrigation solution

    Application of Tranexamic acid in arthroscopic irrigation solution

  • ProcedureNo application of Tranexamic acid in arthroscopic irrigation solution

    No application of Tranexamic acid in arthroscopic irrigation solution

06

What researchers measure

Primary outcomes

  1. Arthroscopic Visual Clarity

    Effect of TXA in arthroscopic irrigation solution to Arthroscopic Visual Clarity

    Time frame: Intra-operatively

Secondary outcomes

  1. Post-operative Pain Evaluation

    Visual Analog Scale (VAS)

    Time frame: Up to the 2nd post-operative day

07

Study locations

1 site
  • Ataşehir Florence Hospital
    Istanbul, Turkey
08

References and documents

Individual participant data

Plan to share: No — There is no plan to share the IPD.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05453266
Lead sponsor
Florence Nightingale Hospital, Istanbul
Responsible party
Celaleddin BILDIK (Principal Investigator, Florence Nightingale Hospital, Istanbul) — Principal investigator
First posted
Jul 12, 2022
Start date
Jan 1, 2022
Primary completion
Jun 5, 2022
Completion
Jun 10, 2022
Last update
Jul 12, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion